

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**APPOINTMENT AND RESIGNATION OF INDEPENDENT
NON-EXECUTIVE DIRECTOR
AND
CHANGE OF MEMBER OF BOARD COMMITTEES**

The Board is pleased to announce that Dr. Hong Yan has been appointed as an independent non-executive Director and a member of the Audit Committee with effect from 15 June 2018.

The Board further announces that Dr. Lap-Chee Tsui has resigned from his position as an independent non-executive Director and a member of the Audit Committee with effect from 15 June 2018.

**APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND
MEMBER OF BOARD COMMITTEES**

The board (the “**Board**”) of directors (the “**Directors**”) of China NT Pharma Group Company Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) is pleased to announce that Dr. Hong Yan (“**Dr. Yan**”) has been appointed as an independent non-executive Director of the Company and a member of the audit committee (“**Audit Committee**”) of the Company, with effect from 15 June 2018 (the “**Appointment**”).

Dr. Yan, aged 52, is a professor of finance at the Shanghai Advanced Institute of Finance (SAIF) of Shanghai Jiao Tong University, where he serves as the deputy dean as well as the deputy director of China Academy of Financial Research. He is also a director of the China Hedge Fund Research Center. Before he joined SAIF as a full-time teaching staff, Dr. Yan was a tenured faculty member at the Moore School of Business in the University of South Carolina, the United States of America. Previously, he was on the faculty at the University of Texas at Austin and was a visiting academic scholar at the Securities & Exchange Commission and the Federal Reserve of the United States. He was also a visiting professor of the University of Hong Kong and Cheung Kong Graduate School of Business. Dr. Yan holds a Doctor of Philosophy degree (Ph.D.) in Finance from the University of California, Berkeley, and also holds a Ph.D. in Applied Physics from the University of Michigan.

Dr. Yan's research areas include credit risk, asset pricing, derivatives securities and investment management and financial intermediaries (including mutual funds, hedge funds and financial analysts). He has published research papers in top academic journals such as Journal of Finance, Journal of Financial Economics and Review of Financial Studies. His research on credit default swaps has been recognized by the Institute for Quantitative Research in Finance in the United States in 2007, He also earned the Crowell Prize in Investment Management in 2010 and a number of Best Paper Awards at international academic conferences.

Dr. Yan currently serves as a managing editor of the <<International Review of Finance>>, which is the journal of Asian Financial Cooperation Association. He chaired the paper review committee for the China International Conference in Finance (CICF) in 2013 and 2014, and has served on judging committees for several major international financial conferences. He also serves as a member of the paper review committee of more than a dozen of international academic journals in economics and finance. In addition, he sits on the advisory boards of several academic and financial institutions and was selected into Shanghai's "Thousand Talents Plan".

As at the date of this announcement, save as disclosed above, Dr. Yan did not hold any other positions with the Company or other members of the Group and did not hold any other directorship in any listed company in the last three years or does not hold any other major appointments and qualifications.

As at the date of this announcement, save as disclosed above, Dr. Yan has no relationship with any other Directors, senior management, substantial shareholders or controlling shareholder of the Company, or any of their respective associates as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

As at the date of this announcement, Dr. Yan does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong).

Dr. Yan has entered into an appointment letter with the Company for a term of three years commencing from 15 June 2018, subject to termination in certain circumstances as stipulated in the appointment letter. Dr. Yan is also subject to retirement by rotation and re-election at the annual general meeting in accordance with the memorandum and articles of association of the Company. Pursuant to his appointment letter, the annual remuneration of Dr. Yan as an independent non-executive Director of the Company is HK\$250,000. Such remuneration is determined with reference to the Company's performance and profitability, as well as the prevailing market conditions.

As at the date of this announcement, save as disclosed above, to the best knowledge of the Board, there is no other information which is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters in relation to the Appointment that need to be brought to the attention of the shareholders of the Company.

The Board would like to extend its warm welcome to Dr. Yan for his new appointment as member of the Board.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND MEMBER OF BOARD COMMITTEES

The Board further announces that Dr. Lap-Chee Tsui (“**Dr. Tsui**”) resigned from his position as an independent non-executive Director of the Company, a member of the Audit Committee with effect from 15 June 2018 due to personal reasons.

Dr. Tsui has confirmed that he has no disagreement with the Board and there are no other matters with respect to his resignation that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its sincere gratitude to Dr. Tsui for his valuable contribution to the Company during his tenure of service.

By order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 15 June 2018

As at the date of this announcement, the executive directors of the Company are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive directors of the Company are Dr. Qian Wei and Ms. Lou Jianying; and the independent non-executive directors of the Company are Mr. Patrick Sun, Mr. Yu Tze Shan Hailson and Dr. Hong Yan.